immunogenicity

India Rolls Out COVID-19 Vaccine Doses for Children Aged 12 to 14 Years

COVID: Govt Panel Recommends Phase 3 Trial of Covovax as Booster for Adults

DCGI Okays Covaxin For Young Adults Aged 12-18 Years, With Some Conditions

Bharat Biotech Releases Long-Awaited Covaxin Phase 3 Data, Claims 77.8% Efficacy

In Pivotal COVID-19 Vaccine Trial, CureVac Disappoints With 47% Efficacy

Johnson & Johnson In Talks With Indian Government to Trial Single-Dose Vaccine

Expert Panel Seeks Additional Data From Dr Reddy’s Laboratories on Sputnik V